Despite the clinical success of immune checkpoint blockade (ICB) therapy in solid tumors (Zappasodi et al., 2018a; Zappasodi et al., 2018b; Ribas and Wolchok, 2018), B-cell lymphomas remain largely refractory to these treatments, with the exception of Hodgkin’s lymphoma, where PD-L1 (programmed death-ligand 1) constitutes a direct tumor target (Zappasodi et al., 2015; Ansell, 2019; Armand et al., 2021a). Here, CD274 is linked to neoplasm.